Efficacy and safety of tenoxicam (Texared®) in ankylosing spondylitis: results of the prospective single-centre controlled study «ASTERIA»
Open Access
- 1 November 2025
- journal article
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 63 (5) , 477-482
Abstract
The aim of the study – to evaluate the safety and influence of tenoxicam (Texared®) on the duration and severity of morning stiffness, spinal pain at night, activity and function in patients with ankylosing spondylitis (AS) Materials and methods. The study included 30 patients (aged 18 to 60) with AS who sequentially sought medical care at the V.A. Nasonova Research Institute of Rheumatology and voluntarily signed an informed consent form to participate in the study. Most patients (66.7%) were male. The average age of patients was 37.6±9.5 years, and the average duration of the disease was 134.5±92.3 months. HLA-B27 antigen positivity was detected in 76.7% of cases. All patients who voluntarily agreed to participate in the study and signed an informed consent form at the initial visit were prescribed tenoxicam (Texared®) at a daily dose of mg. At week 0, 14 days and 90 days (3 months) after the start of therapy, standard clinical and laboratory examinations were performed. Results and discussion. On the background of regular tenoxicam administration, most patients with AS achieved a reduction in clinical parameters of disease activity compared to baseline and its dynamics after 90 days: a decrease in BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) indices to 3.8 (pConclusion. In patients with high and very high AS activity, tenoxicam (Texared®) therapy has been shown to have a positive effect on disease activity, including the severity of night-time back pain and the severity and duration of morning stiffness. The drug is well tolerated and has a favourable safety profile.Keywords
This publication has 14 references indexed in Scilit:
- Response to: Correspondence on “ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update” by Braun et alAnnals of the Rheumatic Diseases, 2023
- Treatment strategies in axial spondyloarthritis: what, when and how?Rheumatology, 2020
- Nonsteroidal anti-inflammatory drugs and cardiovascular risk – a matter of indicationSeminars in Arthritis and Rheumatism, 2020
- 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial SpondyloarthritisArthritis Care & Research, 2019
- Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritisRheumatology, 2016
- Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trialsAnnals of the Rheumatic Diseases, 2016
- Long-Term Frequent Use of Non-Steroidal Anti-Inflammatory Drugs Might Protect Patients with Ankylosing Spondylitis from Cardiovascular Diseases: A Nationwide Case-Control StudyPLOS ONE, 2015
- Validation exercise of the Ankylosing Spondylitis Assessment Study (ASAS) group response criteria in ankylosing spondylitis patients treated with biologicsArthritis Care & Research, 2004
- The Pittsburgh sleep quality index: A new instrument for psychiatric practice and researchPsychiatry Research, 1989
- Evaluation of Diagnostic Criteria for Ankylosing SpondylitisArthritis & Rheumatism, 1984